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Nonmelanoma skin cancers (squamous cell and basal cell carcinomas) occur at an epidemic rate in many countries with the
worldwide incidence increasing. The sun-exposed head and neck are the most frequent sites for these cancers to arise and in
most patients diagnosed with a cutaneous squamous cell carcinoma, local treatment is usually curative. However, a subset is di-
agnosed with a high-risk cutaneous squamous cell carcinoma. High-risk factors include size (>2cm), thickness/depth of invasion
(>4mm), recurrent lesions, the presence of perineural invasion, location near the parotid gland, and immunosuppression. These
patients have a higher risk (>10–20%) of developing metastases to regional lymph nodes (often parotid nodes), and in some cases
also of experiencing local morbidity (perineural invasion), based on unfavourable primary lesion and patient factors. Despite
treatment, many patients developing metastatic cutaneous squamous cell carcinoma experience mortality and morbidity usually
as a consequence of uncontrolled metastatic nodal disease. It is therefore important that clinicians treating nonmelanoma skin
cancers have an understanding and awareness of these high-risk patients. The aim of this article is to discuss the factors that deﬁne
a high-risk patient and to present some of the issues pertinent to their management.
Copyright © 2007 Michael J. Veness. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Nonmelanoma skin cancers (NMSC) are a major public
health concern in Australia [1] and around the world and
although most patients are cured, a minority will die of cu-
taneous SCC (cSCC), usually in the setting of metastases to
regional lymph nodes of the head and neck (HN) [2]. Most
lesions (80–90%) develop on the sun-exposed HN in older
Caucasian males with the overall incidence of patients with
a cSCC developing metastases to regional lymph nodes re-
ported as low (<5%) [3].
The majority of patients treated in the community with
as m a l l( <2cm), thin (<4mm), and previously untreated
cSCC will not develop nodal metastases and can be clas-
siﬁed as low-risk. However, the incidence of nodal metas-
tases in patients referred to a tertiary referral hospital is often
much higher (10–20%) secondary to patients having high-
riskfactors[4–6]. Patients with high-risk cSCC have a higher
risk of developing metastases to regional lymph nodes based
on both unfavorable primary lesion and also patient factors
(Table 1).
The deﬁnition of a patient with a high-risk cSCC is often
underappreciated by clinicians and is not well documented
in the literature. The current TNM (tumor, node, metas-
tases) staging system for cSCC does not incorporate im-
portant prognostic factors (discussed below) such as thick-
ness/depth of invasion when assigning T stage [7]. Size alone
(e.g., T1 ≤ 2cm) is the main criterion used. With emerging
data on high-risk cSCC and the risk associated with other
factors there is a need to investigate an improved and more
prognostic staging system. Similarly, pathology reports of-
ten lack important data such as thickness/depth of invasion,
gradeorthepresenceofperineuralandlymphovascularinva-
sion. As well, factors such as lesion location and the patient’s
immune state are also important to note. In a recent com-
prehensive review Cassarino et al. [6] attempted to classify
histological subtypes of cSCC based on the metastatic poten-
tial they exhibit. High-risk (>10% risk) subtypes included de
novocSCCandcSCCarisingisassociationwithpredisposing
factors (e.g., immunosuppression, burn scars).
Despite some limitations, patients with high risk cSCC
can be identiﬁed and clinicians should be aware so that ap-
propriatemanagementcanberecommended.Theaimofthis
article is to discuss those factors that make a patient diag-
nosed with a cSCC at higher risk of developing metastases.2 Journal of Biomedicine and Biotechnology
Table 1: High-risk factors (patients often have multiple high-risk
factors present).
Factor
(1) Large size (>2cm).
(2) Thick or deeply invasive lesion (>4mm).
(3) Incomplete excision (<4mm).
(4) Recurrent setting.
(5) High-grade or desmoplastic lesion.
(6) Presence of perineural invasion.
(7) Presence of lymphovascular invasion.
(8) Located near the parotid gland (ear,
temple, forehead, ant. scalp).
(9) Immunosuppressed state (e.g., transplant recipient).
2. LESION SIZE
Lesion size is reported as an important predictor for devel-
oping nodal metastases. However size alone is probably a
weak independent predictor although many studies report a
threshold size of approximately 2cm beyond which patients
have an increasing propensity to metastases to nodes. In a se-
ries of 200 patients with cSCC, 12.5% developed metastatic
cSCC with the authors reporting a signiﬁcant diﬀerence in
the rate of nodal metastases from various primary sites of the
HN using a 2cm threshold size (13% versus 68%; P = .004)
[4]. In a large review Rowe et al. [8] reported the incidence
of metastases was 30% for cSCC >2cmversus9%forcSCC
<2cm.M ullenetal.[9] identiﬁed tumor size >2cmasan
independent predictor on univariate analysis for recurrence
or death, although size did not remain a signiﬁcant pre-
dictor on multivariate analysis. In a study of patients with
metastatic cSCC to HN nodes, the authors compared the
data to nonmetastatic historical controls and found a diﬀer-
ence in the number of patients with cSCC >2cm (19% non-
metastatic versus 81% metastatic) [10]. Moore et al. [5]r e -
ported median lesion size as highly signiﬁcant (3cm versus
2cm;P = .0002) in a study of 40 patients with metastatic
cSCC when compared to 153 cSCC patients without metas-
tases. Veness et al. [11] reported median size of cSCC of only
1.5cm with only 30% of patients having a cSCC >2cmina
large study of 266 patients with metastatic nodal cSCC of the
HN. This latter study would suggest that other factors (i.e.,
tumor thickness, site, etc.) are also likely to contribute to the
risk of developing metastases. Of note, 20–30% of patients
may not have an identiﬁable nearby high-risk index lesion in
the setting of nodal metastases. However, most patients in-
variably will have had a past history of NMSC treated in the
HN.
3. THICKNESS/DEPTH OF INVASION
Thickness (or depth of invasion) is an important predictor
of metastases. Depth of invasion >4mm is associated with
an increasing risk. In a study of patients with lower lip SCC,
there was a signiﬁcant diﬀerence in mean depth of invasion
in node negative patients compared with those developing
nodal metastases (4.2mm versus 11.2mm; P<. 001) [12].
In another study of patients with metastatic cSCC of the HN
only 17% with a lesion <4mm metastasised compared with
83% with lesions >4mm[9].
Patients with lesions <4mm thick have a low incidence
of nodal metastases. A large study of 550 patients with 594
cSCC (including 149 lip SCC) documented a 4% rate of
nodal metastases with only 7 patients (2.9%) with a tu-
mour ≤ 5mm thick developing metastases compared with
14 (17.5%) patients with a tumour >5mm thick. Of note,
no patient with a superﬁcial cSCC (<2mm thick) developed
metastases [13].




tic factors in patients with cSCC, those with a tumor <4mm
or Clark levels I–III had a metastatic rate of 6.7% compared
to 45.7% in those with a tumor >4mm or Clark level IV-V
[8].
4. INCOMPLETE EXCISION/RECURRENCE
Up to 50% of patients with a positive margin with a cSCC
will locally recur with a subsequent increased risk of devel-
oping nodal metastases [14]. In a study of patients with lip
SCC, those with recurrent lip SCC experienced a signiﬁcant
diﬀerence in nodal metastases compared with those not de-
veloping local recurrence (15% versus 2%; P<. 0001) [15].
In a large review of the literature, patients experienced a 32%
and 45% incidence of nodal metastases in the setting of re-
current lip SCC and ear SCC, respectively [8].
There is no consensus in regards to the deﬁnition of an
acceptable surgical margin in cSCC. In a series of patients
undergoing intraoperative frozen section analysis to achieve
a minimum of a 3mm surgical margin, only 3% recurred
with a median follow up of 5.1 years [16]. Another study
of patients with cSCC <2cm in diameter found that with a
4mm excision margin 95% had negative excision margins.
With lesions >2cm a 6mm margin would achieve a 95% rate
of negative excision margins [17]. The authors subsequently
recommended 6mm margins with high-grade tumours or
those located in high-risk areas. In concordance with these
ﬁndings in another study of 150 excised NMSC (25% cSCC)
a 4mm surgical margin resulted in clearance in 97% of cases
comparedwitha2mmexcisionmarginachievingthisinonly
78% of cases [18]. In one study of metastatic cSCC to HN
nodes 51% of patients developing nodal metastases had a re-
current primary lesion [19]. Therefore a recommendation of
observation in patients with an inadequately excised cSCC
(<4mm) must be considered very carefully in light of the in-




Poorly diﬀerentiated cSCC are more likely to be associated
with the development of regional metastases. In a study ofMichael J. Veness 3
571 patients with cSCC, there was a signiﬁcant diﬀerence
in the rate of metastases for high-grade lesions compared to
other grades (17% versus 4%; P = .004) [20]. The incidence
of poorly diﬀerentiated lesions in one series of patients with
metastatic cSCC was signiﬁcantly increased in patients de-
veloping metastases (44% versus 5%; P<. 01) [4]. There
are also data that desmoplastic SCC, an aggressive histolog-
ical variant of SCC, possesses a high propensity to regional
metastases especially with increasing tumor thickness. Using
Broder’s classiﬁcation, over a quarter of patients (27%) in
one study with a desmoplastic SCC were assigned as grade
IV diﬀerentiation compared to only 11% with a nondesmo-
plastic cSCC [13].
6. PERINEURAL INVASION
Perineural invasion (PNI) occurs in ∼5% of patients with
cSCC and is usually an incidental ﬁnding but is reported to
be associated with a higher incidence of nodal metastases
compared to patients without PNI. In a large study from MD
Anderson, Texas, there was a signiﬁcant increase in both re-
gional (35% versus 15%; P<. 0005) and distant metastases
(15% versus 3.3%; P<. 0005) for patients diagnosed with
PNI compared to those without [20] .I nal a r g es t u d yo f1 3 5
patientswithPNIandtreatedwithradiotherapy+/−surgery,
half of all failures in patients with microscopic PNI were in
regional nodes, prompting the authors to recommend elec-
tive nodal treatment in patients with PNI [21]. A study com-
paring prognostic features of patients with metastatic and
nonmetastatic lip SCC also reported a highly signiﬁcant dif-
ference in the presence of PNI (41% versus 5%; P<. 0001)
[22].
It should also be noted that PNI may also lead to sig-
niﬁcant morbidity and mortality from the involvement of
cranial nerves (usually facial or trigeminal) leading to skull
base/intracranial spread. The optimal treatment of patients
with PNI remains unclear although wide ﬁeld radiotherapy
is an important modality in many patients. Patients diag-
nosed even with focal PNI, especially if located in the peri-
orbital region, should be recommended appropriated treat-
ment. The ﬁnding of PNI away from the actual tumor mass,
and often extending to excision margins, indicates progres-
sive perineural spread and a need for further treatment. Re-
cent data from the University of Florida suggests patients
with asymptomatic microscopic (incidental) PNI have a sig-
niﬁcantly better outcome compared to patients presenting
with clinically or radiologically positive PNI (local control at
5 years 87% versus 55%; P = .0006) [21, 23].
7. SITE
Patients with cSCC located within the lymphatic drainage
of the parotid gland (on or around the external ear, tem-
ple, forehead, anterior scalp) or lower lip are associated
with a higher incidence of metastases. The scalp is often a
site for high-risk cSCC and, in particular, patients can de-
velop satellite or in-transit metastases which carry a poor
prognosis [24]. Most patients developing metastatic nodal
cSCC of the HN do so to the parotid and/or upper cervical
nodes [24, 25]. There are advocates of elective nodal dissec-
tion in select high-risk patients with lesions located on the
ear/preauricular region [26, 27]a n dl i p[ 28]. Accurately pre-
dicting patients that may develop nodal relapse is diﬃcult,
however, clinicians should consider patients with recurrent
SCC that are >4mm thick and in the vicinity of the parotid
gland (ear, lateral scalp, forehead, temple, cheek) at higher
risk of developing parotid nodal metastases. It is these pa-
tients that should be considered as candidates for the elective
treatment of parotid nodes. Depending on the type of treat-
ment to the primary cutaneous lesion, elective nodal treat-
ment may entail either a superﬁcial parotidectomy, or alter-
natively, radiotherapy to the parotid gland.
8. IMMUNOSUPPRESSION
Immunosuppression, particularly in the setting of an organ
transplantation recipient (OTR), often leads to signiﬁcant
morbidity from NMSC, usually cSCC. A subset of cSCC in
OTR is aggressive in nature with rapid growth and the devel-
opment of regional and distant metastases. In an Australian
study of 619 cardiothoracic transplant recipients, 26 devel-
opedanaggressiveNMSCwithmostdiagnosedwithapoorly
diﬀerentiatedcSCC[29].Deathoccurredin13ofthe26with
10 patients dying from systemic disease. Martinez et al. [30]
reportedtheoutcomeof60OTRallwithmetastaticskincan-
cer(85%cSCC)notingthat27%ofpatientshadanunknown
index lesion. In this study median primary lesion size was
12mm and median depth of invasion was 3.2mm. Three-
year disease speciﬁc survival was only 56%. This would sug-
gest a smaller lesion size and lesser depth of invasion asso-
ciated with the development of metastatic cSCC and a sig-
niﬁcantlyworseoutcomecomparedwithimmunocompetent
(IC) patients. In another study comparing IC and OTR pa-
tientsasigniﬁcantproportionofOTRhadthick(>5mm)tu-
mors and exhibited early dermal invasion compared with IC
patients [31]. Of note, patients immunosuppressed as a con-
sequence of chronic lymphocytic leukemia (CLL) also have a
similar increased risk of cutaneous SCC and poor outcome
from developing metastases [32]. In many cases, the level of
immunosuppression cannot be markedly reduced. The basic
tenets of obtaining adequate surgical margins and examining
forPNIareespeciallyapplicabletothisgroupofpatients.Ad-
juvant radiotherapy to incompletely excised cSCC, or those
with PNI, should be strongly considered. Close liaison with a
transplant physician is also important.
9. LYMPHOVASCULAR INVASION
Recent evidence suggests that the presence of lymphovascu-
lar invasion may increase the risk of developing nodal metas-
tases. Moore et al. [5] documented lymphovascular invasion
as an independent predictor of nodal metastases on multi-
variate analysis (OR 7.54; P<. 00001). In this study 40%
of patients with nodal metastases had lymphovascular inva-
sioncomparedwithonly8%ofnodenegativepatients.Other
studiesofhigh-riskcSCCalsoreportthepresenceoflympho-
vascular invasion although fail to ﬁnd any signiﬁcant impact
on outcome [2–4].4 Journal of Biomedicine and Biotechnology
Table 2:Indicationsforradiotherapyinhigh-riskcutaneoussquamouscellcarcinoma.DXR:deepenergyphotons(orthovoltage);Gy:Gray;
RTx: radiotherapy; SXR: superﬁcial energy electrons; Sx: surgery; #: daily fraction of radiotherapy; ¶: surgery would compromise function
and/or cosmesis.
Setting Indication Dose/fractionation/technique
Adjuvant local RTx Inadequate excision and
re-excision not possible¶
50–55 Gy in 20–25#s using
SXR/DXR or low-energy electrons
with bolus and 1.5–2cm margins
Adjuvant nodal RTx
(post node dissection)
Multiple metastatic nodes and/or
extranodal spread
55–60 Gy in 25–30#s using
megavoltage photons
Elective nodal RTx
(elective Sx also an option)
Multiple high-risk features and
proximity to parotid gland
50 Gy in 25#s using
moderate-energy electrons
or megavoltage photons
RTx to neural pathway (include
brainstem in select patients)
Perineural invasion in high-risk
location (e.g., periorbit or
parotid gland)




Dermal metastases (usually scalp-based) All patients: deﬁnitive or adjuvant RTx
55–60 Gy in 25–30#s using a
wide ﬁeld technique (4-5cm
margins) (consider whole scalp
RTx in some patients)
The consequences of cSCC in dermal lymphatic vessels,
which is uncommonly reported, is unclear but may increase
a patient’s risk of relapse and may explain the phenomenon
of in-transit metastases [33]. Patients that develop in-transit
metastases are best treated with wide ﬁeld high-dose radio-
therapy encompassing the sites of gross disease plus gener-
ous4-5cmmarginstotreatpotentialsubclinicaldermallym-
phatic spread.
10. GUIDELINES AND RECOMMENDATIONS
The National Comprehensive Cancer Network (NCCN) has
created an algorithm to aid clinicians [34]. While not en-
tirely evidenced-based, the authors consider patients with
tumors ≥ 4mm thick, Clark level IV-V, moderate to poor
diﬀerentiation, PNI present and recurrent as high-risk and
recommend wide excision (10mm margins if achievable)
and adjuvant radiotherapy if warranted. No speciﬁc rec-
ommendation is made on the elective treatment of re-
gional nodes in high-risk patients. The British Association
of Dermatologists recently published guidelines for man-
aging a patient with cSCC [35]. Patients were considered
at greater risk of local recurrence and developing metas-
tases based on six variables: site (lip, ear, non-sun-exposed
sites), size (>2cm), depth (>4mm or Clark level V), grade
(poorly diﬀerentiated), host immunosuppression (immuno-
suppressed), and presentation (recurrent). The guidelines
did not support electively treating lymph nodes because of
insuﬃcient evidence. The American Academy of Dermatol-
ogists also recommended patients with selected recurrent
cSCC and those with increased biological aggressiveness to
undergo Moh’s micrographic surgery [36]. No recommen-
dation was made on electively treating lymph nodes in high-
risk patients. The International Transplant-Skin Cancer Col-
laboration (ITSCC) recently published guidelines for man-
aging OTR with cSCC [37]. All features considered high-
risk in non-OTR patients were also deemed high-risk in
OTR patients although the authors considered a much lower
size threshold (>0.6cm for “mask” facial area and >1cm
for cheek, forehead, scalp). Moh’s micrographic surgery was
recommended or alternatively wide local excision with 6–
10mm margins.
Clinicians managing patients with high-risk cSCC need
to consider multiple factors prior to recommending that fur-
ther treatment with radiotherapy is an important option in
many patients (Table 2). Patients will often have many high-
risk factors and therefore the beneﬁt from recommending,
forexample,wideﬁeldadjuvantradiotherapy,mayjustifythe
potential toxicity and cost. The evidence for many clinical
settings is still emerging and further research is needed.
11. SENTINEL NODE BIOPSY
There are only limited data to guide clinicians on the role
of sentinel node biopsy (SNB) in HN NMSC. In a recent
large systematic review on the topic, a total of 692 patients
were identiﬁed, however only 85 patients had a nonanogen-
ital cSCC and many of these were extremity lesions [38].
Many studies have also reported on lip SCC although as pre-
viously discussed cSCC located around the parotid/upper
neck carry the highest risk of developing nodal metastases.
Further studies are still needed to better deﬁne the role of
SNB in HN NMSC.
12. CONCLUSION
Most patients with cSCC will not develop nodal metas-
tases and therefore IC patients with small (<2cm), thin
(<4mm), adequately excised (>4mm margins), and previ-
ously untreated cSCC are not candidates for further treat-
ment. However, accurately predicting patients at high-riskMichael J. Veness 5
and, therefore, justifying the elective treatment of ﬁrst eche-
lon lymph nodes is diﬃcult. Despite this, patients with more
than one high-risk factor (thick/deeply invasive >4mm,
>2cm in diameter, located near the parotid gland, especially
in the recurrent setting) should be considered at risk of de-
veloping nodal metastases. In such cases, elective treatment
(surgery or radiotherapy) to ﬁrst echelon nodes may be of
beneﬁt and referral to a multidisciplinary head and neck
cancer service is encouraged [39]. At a minimum, patients
should be followed closely (2-3 months) for at least 3-4 years
since late nodal relapse is well documented.
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